Jefferies has upgraded Crinetics (CRNX) to buy, citing a recent pullback in the stock on investor concerns about Phase 2 data for the company's drug atumelnant. Read more here.

Fintel reports that on January 22, 2025, Jefferies upgraded their outlook for Crinetics Pharmaceuticals (NasdaqGS:CRNX) from ...

Canaccord Genuity analyst Maria Ripps upgraded the rating for Netflix, Inc. NFLX from Hold to Buy and raised the price target ...

Jefferies analyst Dennis Ding upgraded Crinetics (CRNX) to Buy from Hold with an unchanged price target of $55. The firm cites the pullback in ...

Jefferies upgraded Crinetics Pharmaceuticals stock, moving the rating from Hold to Buy, while maintaining a price target of $55.00. The decision follows a notable decline in share price from $60 to ...

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...

Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology and healthcare ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Crinetics Pharmaceuticals (CRNX – Research Report), ...

Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC ...

Crinetics Pharma reports positive results from phase 2 trial of atumelnant in congenital adrenal hyperplasia: San Diego Monday, January 13, 2025, 16:30 Hrs [IST] Crinetics Pharmac ...

Crinetics Pharmaceuticals Inc (CRNX) stock saw a decline, ending the day at $40.59 which represents a decrease of $-7.91 or -16.31% from the prior close of $48.5. The stock opened at $46.64 and ...